![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
MARA Holdings
MARA
Strategy
MSTR
Adobe
ADBE
4
Coinbase
COIN
5
Salesforce
CRM
US Stock MarketDetailed Quotes
EMN Eastman Chemical
- 75.645
- -0.065-0.09%
Trading Apr 29 09:42 ET
8.73BMarket Cap9.64P/E (TTM)
75.995High75.315Low52.27KVolume75.090Open75.710Pre Close3.95MTurnover0.05%Turnover Ratio9.86P/E (Static)115.41MShares112.49452wk High1.49P/B8.66BFloat Cap70.90052wk Low3.28Dividend TTM114.43MShs Float115.473Historical High4.34%Div YieldTTM0.90%Amplitude5.580Historical Low75.641Avg Price1Lot Size
Eastman Chemical Stock Forum
Sign in to post a comment
Eastman Chemical's statutory earnings may have been distorted by unusual items, suggesting that its true underlying earnings power could be less than its statutory profit. There are also 2 warning signs for Eastman Chemical that investors should be aware of.
EPS growth and falling share price mismatch suggests a shift in market perception of the company. Recent sell-off could be a long-term growth opportunity, but investors should heed 2 warning signs for Eastman Chemical.
A decline in earnings per share and ongoing risk to future dividends make Eastman Chemical less appealing for dividend-focused investors despite efforts to increase the dividend payout ratio.
1
Despite Eastman Chemical's fair trading price, future buying opportunities may arise from the stock's volatility. The company's bright outlook, propelled by a predicted profit doubling, might lead to increased cash flow and share valuation. However, a thorough balance sheet analysis is recommended before investing.
Analyst Jeffrey Zekauskas from J.P. Morgan predicts Eastman Chemical's earnings to rebound in 2024. Poor performance in 2023 due to market challenges, but possible recovery driven by dividends and good free cash flow expected.
Gapping up
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
10
3
GOLDMAN SACHS
• $Bausch + Lomb Corp. (BLCO.US)$ Goldman Sachs analyst Amit Hazan initiated coverage of Bausch + Lomb with a Neutral rating and $22 price target, implying 22% upside potential. The analyst sees Bausch + Lomb's current offering and pipeline as positioning it well to maintain or expand share in the "attractive and durable' eye care market.
• $Steel Dynamics (STLD.US)$ Goldman Sachs analyst Emily Chieng downgraded Steel Dynamics to Neutral...
• $Bausch + Lomb Corp. (BLCO.US)$ Goldman Sachs analyst Amit Hazan initiated coverage of Bausch + Lomb with a Neutral rating and $22 price target, implying 22% upside potential. The analyst sees Bausch + Lomb's current offering and pipeline as positioning it well to maintain or expand share in the "attractive and durable' eye care market.
• $Steel Dynamics (STLD.US)$ Goldman Sachs analyst Emily Chieng downgraded Steel Dynamics to Neutral...
21
31
Upgrades
• $Grab Holdings (GRAB.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $3.04
• $Linde (LIN.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $355
• $Magellan Midstream (MMP.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT $56 (from $54)
• $Mercury Systems (MRCY.US)$: Baird Upgrades to Outperform from Neutral - PT $72 (from $56)
• $Nurix Therapeutics (NRIX.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT...
• $Grab Holdings (GRAB.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $3.04
• $Linde (LIN.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $355
• $Magellan Midstream (MMP.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT $56 (from $54)
• $Mercury Systems (MRCY.US)$: Baird Upgrades to Outperform from Neutral - PT $72 (from $56)
• $Nurix Therapeutics (NRIX.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT...
16
3
7
Gainers:
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
16
1
112
No comment yet
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
JACKmusk : Good buy